Sopan Pharmaceuticals IPO Launch Set for Baisakh
1st April 2026, Kathmandu
The Sopan Pharmaceuticals IPO Nepal Launch has been officially announced, with the company preparing to issue shares to the general public starting from Baisakh 2, 2083 (April 15, 2026).
Sopan Pharmaceuticals IPO Launch
Sopan Pharmaceuticals Limited is entering the primary market of Nepal with a significant offering aimed at retail investors. This IPO marks the second phase of the public issuance of the company, following the successful allocation of shares to Nepali citizens working abroad, company employees, and mutual funds.
As the healthcare sector in Nepal continues to expand, the entry of pharmaceutical manufacturing companies into the stock exchange provides a unique diversification opportunity for investors. The Sopan Pharmaceuticals IPO Nepal launch is expected to attract high subscription rates given the essential nature of the industry.
IPO Details and Share Allocation
Under the Sopan Pharmaceuticals IPO Nepal Launch, the company will issue a total of 3,474,900 shares to the general public. Each share carries a face value of 100. Previously, the company had received formal approval from the Securities Board of Nepal (SEBON) to issue a total of 4,290,000 shares, representing 25 percent of its total issued capital of 1.71 billion.
The strategic allocation breakdown is as follows:
Foreign Employment Category: 429,000 shares already issued to Nepali workers abroad.
Mutual Funds: 214,500 shares reserved for institutional investment.
Company Employees: 171,600 shares allocated to the dedicated staff of the firm.
Advertisement
General Public: The remaining 3,474,900 shares now offered to the nationwide retail market.
Application Process and Timeline
Investors interested in the Sopan Pharmaceuticals IPO Nepal Launch can apply for a minimum of 10 shares (1,000) and a maximum of 11,000 shares. The application window will remain open until Baisakh 6. However, if the issue is not fully subscribed within the initial period, the deadline may be extended until Baisakh 16.
Applications can be submitted through the C-ASBA system via banks and financial institutions approved by SEBON. Most retail investors are expected to apply online using the popular MeroShare platform.
Issue Manager and Credit Rating
The IPO is being managed by NMB Capital Limited, which has been appointed as the official issue and sales manager. In terms of creditworthiness, the company has received a CARE-NP Single B rating from CARE Ratings Nepal. This rating indicates a relatively high risk in the ability of the company to meet its financial obligations compared to more stable sectors.
Despite the risk rating, the company reports a healthy internal rate of return (IRR) of 23.63 percent. This figure may appeal to aggressive investors seeking higher potential returns within the pharmaceutical production landscape of Nepal.
Investment Perspective on the Pharma Sector
The Sopan Pharmaceuticals IPO Nepal Launch provides a rare opportunity for investors to participate in the growing pharmaceutical manufacturing sector of the country. With an increasing national demand for localized healthcare products and life-saving medicines, companies in this sector are gaining significant attention on the Nepal Stock Exchange (NEPSE).
However, potential investors should carefully evaluate the financial health, high-risk rating, and current market volatility of the company before making their final investment decisions.
Key Highlights for Investors
- Total Public Shares: 3,474,900 units
- Face Value: 100 per share
- Opening Date: Baisakh 2, 2083
- Closing Date: Baisakh 6, 2083
- Minimum Investment: 1,000 (10 shares)
- Risk Rating: CARE-NP Single B (High Risk)
Conclusion
The Sopan Pharmaceuticals IPO Nepal Launch is a key event in the capital market of Nepal, offering retail investors direct access to a new pharmaceutical player. With a structured allocation, a clear timeline, and a highly accessible application process through digital channels, the IPO is expected to draw considerable interest from the public. Investors are encouraged to apply within the deadline and carefully assess the risk-return profile of the pharmaceutical industry before participating in this offering.
For More: Sopan Pharmaceuticals IPO Launch
